If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCentrica Regulatory News (CNA)

Share Price Information for Centrica (CNA)

Share Price is delayed by 15 minutes
Get Live Data
171.35    3.50 (2.09%)
Bid:
170.80
Ask:
170.90
Spread: 0.10 (0.059%)
Market Cap: £7.76b
CNA Live PriceLast checked at - London Stock Exchange

Intraday Centrica Share Chart

Directorate change

12 May 2026 07:10

RNS Number : 8514D
Centrica PLC
12 May 2026
 

12 May 2026

Centrica plc

('Centrica' or 'the Company')

Centrica appoints Non-Executive Director

Centrica is pleased to announce the appointment of Jonathan Howell as a NonExecutive Director of the Company with effect from 12 May 2026. Jonathan will also become Chair of the Audit and Risk Committee and a member of the Nominations Committee, with effect from 31 July 2026.

Jonathan has significant board-level executive and non-executive experience across FTSE-listed and regulated businesses, with particular expertise in finance, governance, risk and transformation. He is currently a Non-Executive Director and Chair of the Audit Committee of Experian plc and Whitbread plc, and previously served on the boards of Sage Group plc, EMAP plc, FTSE International Ltd and CrestCo Ltd.

Jonathan brings deep financial leadership experience gained in complex, highly regulated environments. Having trained as a Chartered Accountant, his extensive executive career includes roles such as the CFO of Sage Group plc, Close Brothers Group plc and London Stock Exchange Group plc.

Nathan Bostock will step down from the Board, the Nominations Committee, the Safety, Environment and Sustainability Committee and as Chair of the Audit and Risk Committee with effect from 31 July 2026.

Kevin O'Byrne, Chair of Centrica, said:

"I am delighted to welcome Jonathan to the Board. He brings deep financial and regulatory expertise, alongside considerable experience as both a FTSE 100 chief financial officer and audit committee chair. The Board will benefit greatly from Jonathan's judgement, rigour and market experience as Centrica continues to execute its strategy.

On behalf of the Board, I would like to thank Nathan for his significant contribution to Centrica and his leadership of the Audit and Risk Committee. We are grateful for his commitment and support and wish him well for the future as he steps down from the Board at the end of July."

Jonathan Howell said:

"I am pleased to be joining the Board of Centrica. The Company has a clear strategy and a strong focus on disciplined performance. I look forward to working with the Board and management team to support the delivery of long‑term value for shareholders."

Notes:

This appointment is made pursuant to UK Listing Rule 6.4.8.

In accordance with the obligations under UK Listing Rule 6.4.6, Jonathan Howell currently holds the following non‑executive directorships in quoted companies:

· Whitbread plc

· Experian plc

 

Jonathan Howell was previously a director of Sage Group plc.

At the date of this announcement, Jonathan Howell has no beneficial interest in the ordinary shares of Centrica plc.

The Company confirms that there are no further matters requiring disclosure under UK Listing Rules 6.4.6 to 6.4.9 inclusive.

ENDS

Enquiries:

Investors and AnalystsE: ir@centrica.com

MediaT: 01784 843000E: media@centrica.com

Centrica plc is listed on the London Stock Exchange (CNA)Registered Office: Millstream, Maidenhead Road, Windsor, Berkshire SL4 5GD

Registered in England & Wales number: 3033654Legal Entity Identifier number: E26EDV109X6EEPBKVH76ISIN number: GB00B033F229

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAABMITMTIBBMF
Date   Source Headline
31st May 20235:30 pmRNSHolding(s) in Company
30th May 20236:00 pmRNSTransaction in Own Shares
26th May 20236:15 pmRNSTransaction in Own Shares
25th May 20236:00 pmRNSTransaction in Own Shares
25th May 202311:20 amRNSDirector/PDMR Shareholding
24th May 20236:15 pmRNSTransaction in Own Shares
23rd May 20236:25 pmRNSTransaction in Own Shares
22nd May 20236:10 pmRNSTransaction in Own Shares
19th May 20236:20 pmRNSTransaction in Own Shares
19th May 20235:00 pmRNSHolding(s) in Company
19th May 202310:00 amRNSHolding(s) in Company
18th May 20236:30 pmRNSTransaction in Own Shares
18th May 20238:00 amRNSInvestor and Analyst Teach-in
17th May 20236:15 pmRNSTransaction in Own Shares
17th May 20236:00 pmRNSHolding(s) in Company
16th May 20236:15 pmRNSTransaction in Own Shares
16th May 202310:30 amRNSHolding(s) in Company
15th May 20236:15 pmRNSTransaction in Own Shares
12th May 20236:20 pmRNSTransaction in Own Shares
12th May 20234:00 pmRNSHolding(s) in Company
12th May 202310:00 amRNSHolding(s) in Company
11th May 20236:00 pmRNSTransaction in Own Shares
11th May 20233:33 pmRNSNotice of AGM
11th May 20231:30 pmRNSDirector/PDMR Shareholding
11th May 202310:00 amRNSHolding(s) in Company
10th May 20236:10 pmRNSTransaction in Own Shares
9th May 20236:20 pmRNSTransaction in Own Shares
9th May 20233:45 pmRNSHolding(s) in Company
9th May 202310:00 amRNSHolding(s) in Company
5th May 20236:10 pmRNSTransaction in Own Shares
4th May 20236:15 pmRNSTransaction in Own Shares
4th May 20235:15 pmRNSHolding(s) in Company
3rd May 20236:20 pmRNSTransaction in Own Shares
3rd May 20235:15 pmRNSHolding(s) in Company
2nd May 20236:20 pmRNSTransaction in Own Shares
2nd May 20233:30 pmRNSHolding(s) in Company
2nd May 202311:30 amRNSBlock listing Interim Review
2nd May 202311:15 amRNSTotal Voting Rights
28th Apr 20236:20 pmRNSTransaction in Own Shares
27th Apr 20236:00 pmRNSTransaction in Own Shares
27th Apr 20235:30 pmRNSHolding(s) in Company
27th Apr 20235:00 pmRNSHolding(s) in Company
27th Apr 202310:00 amRNSHolding(s) in Company
26th Apr 20236:15 pmRNSTransaction in Own Shares
25th Apr 20236:15 pmRNSTransaction in Own Shares
25th Apr 20234:30 pmRNSDirector/PDMR Shareholding
24th Apr 20236:25 pmRNSTransaction in Own Shares
21st Apr 20236:15 pmRNSTransaction in Own Shares
21st Apr 20232:15 pmRNSHolding(s) in Company
20th Apr 20236:15 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.